Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Studies suggest that regular use of metformin may decrease cancer mortality. We investigated the association between diabetes medication use and cancer survival. Materials and Methods The current study includes 633 breast, 890 colorectal, 824 lung, and 543 gastric cancer cases identified from participants of two population-based cohort studies in Shanghai. Information on diabetes medication use was obtained by linking to electronic medical records. The associations between diabetes medication use (metformin, sulfonylureas, and insulin) and overall and cancer-specific survival were evaluated using time-dependent Cox proportional hazards models. Results After adjustment for clinical characteristics and treatment factors, use of metformin was associated with better overall survival among colorectal cancer patients (hazards ratio [HR], 0.55; 95% confidence interval [CI], 0.34 to 0.88) and for all four types of cancer combined (HR, 0.75; 95% CI, 0.57 to 0.98). Ever use of insulin was associated with worse survival for all cancer types combined (HR, 1.89; 95% CI, 1.57 to 2.29) and for the four cancer types individually. Similar associations were seen for diabetic patients. Sulfonylureas use was associated with worse overall survival for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) among diabetic patients. Similar association patterns were observed between diabetes medication use and cancer-specific survival. Conclusion Metformin was associated with improved survival among colorectal cancer cases, while insulin use was associated with worse survival among patients of four major cancers. Further investigation on the topic is needed given the potential translational impact of these findings.
Abstract
Purpose Studies suggest that regular use of metformin may decrease cancer mortality. We investigated the association between diabetes medication use and cancer survival. Materials and Methods The current study includes 633 breast, 890 colorectal, 824 lung, and 543 gastric cancer cases identified from participants of two population-based cohort studies in Shanghai. Information on diabetes medication use was obtained by linking to electronic medical records. The associations between diabetes medication use (metformin, sulfonylureas, and insulin) and overall and cancer-specific survival were evaluated using time-dependent Cox proportional hazards models. Results After adjustment for clinical characteristics and treatment factors, use of metformin was associated with better overall survival among colorectal cancer patients (hazards ratio [HR], 0.55; 95% confidence interval [CI], 0.34 to 0.88) and for all four types of cancer combined (HR, 0.75; 95% CI, 0.57 to 0.98). Ever use of insulin was associated with worse survival for all cancer types combined (HR, 1.89; 95% CI, 1.57 to 2.29) and for the four cancer types individually. Similar associations were seen for diabetic patients. Sulfonylureas use was associated with worse overall survival for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) among diabetic patients. Similar association patterns were observed between diabetes medication use and cancer-specific survival. Conclusion Metformin was associated with improved survival among colorectal cancer cases, while insulin use was associated with worse survival among patients of four major cancers. Further investigation on the topic is needed given the potential translational impact of these findings.
참고문헌 (39)
- Barone BB, "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and metaanalysis", JAMA, 300, pp.2754~2764 (2008)
- Noto H, "Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis", PLoS One, 7, pp.e33411~ (2012)
- Decensi A, "Metformin and cancer risk in diabetic patients : a systematic review and meta-analysis", Cancer Prev Res(Phila), 3, pp.1451~1461 (2010)
- Zhang P, "Association of metformin use with cancer incidence and mortality : a meta-analysis", Cancer Epidemiol, 37, pp.207~218 (2013)
- Baur DM, "Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort", Metabolism, 60, pp.1363~1371 (2011)
- Bo S, "Cancer mortality reduction and metformin : a retrospective cohort study in type 2 diabetic patients", Diabetes Obes Metab, 14, pp.23~29 (2012)
- Landman GW, "Metformin associated with lower cancer mortality in type 2 diabetes : ZODIAC-16", Diabetes Care, 33, pp.322~326 (2010)
- Currie CJ, "Mortality after incident cancer in people with and without type 2 diabetes : impact of metformin on survival", Diabetes Care, 35, pp.299~304 (2012)
- He X, "Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer", Ann Oncol, 23, pp.1771~1780 (2012)
- Bayraktar S, "Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer", Cancer, 118, pp.1202~1211 (2012)
- Lee JH, "The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus", Int J Cancer, 131, pp.752~759 (2012)
- Ahmed I, "Impact of metformin use on survival in locallyadvanced, inoperable non-small cell lung cancer treated with definitive chemoradiation", J Thorac Dis, 7, pp.346~355 (2015)
- Lin J, "Metformin use and survival after non-small cell lung cancer : a cohort study in the US Military health system", Int J Cancer, 141, pp.254~263 (2017)
- Ramjeesingh R, "A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival", Curr Oncol, 23, pp.e116~e122 (2016)
- Paulus JK, "Metformin, diabetes, and survival among U.S. Veterans with colorectal cancer", Cancer Epidemiol Biomarkers Prev, 25, pp.1418~1425 (2016)
- Lee CK, "Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy", Ann Surg, 263, pp.96~102 (2016)
- Lacroix O, "Impact of metformin on gastric adenocarcinoma survival : a Belgian population based study", Cancer Epidemiol, 53, pp.149~155 (2018)
- Ioacara S, "Cancer specific mortality in insulin-treated type 2 diabetes patients", PLoS One, 9, pp.e93132~ (2014)
- Bowker SL, "Glucose-lowering agents and cancer mortality rates in type 2 diabetes : assessing effects of time-varying exposure", Diabetologia, 53, pp.1631~1637 (2010)
- Suissa S, "Immortal time bias in observational studies of drug effects", Pharmacoepidemiol Drug Saf, 16, pp.241~249 (2007)
- Chaiteerakij R, "Metformin use and survival of patients with pancreatic cancer : a cautionary lesson", J Clin Oncol, 34, pp.1898~1904 (2016)
- Xin W, "Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes : a meta-analysis", Mol Clin Oncol, 8, pp.483~488 (2018)
- Lee SA, "Physical activity patterns and their correlates among Chinese men in Shanghai", Med Sci Sports Exerc, 39, pp.1700~1707 (2007)
- Zheng W, "The Shanghai Women's Health Study : rationale, study design, and baseline characteristics", Am J Epidemiol, 162, pp.1123~1131 (2005)
- "Centers for Disease Control and Prevention" (2018)[URL]
- "ICD10Data.com" (2018)[URL]
- Korn EL, "Time-to-event analysis of longitudinal follow-up of a survey : choice of the time-scale", Am J Epidemiol, 145, pp.72~80 (1997)
- Hanley JA, "Avoiding blunders involving 'immortal time'", Int J Epidemiol, 43, pp.949~961 (2014)
- Belda-Iniesta C, "Metformin : a new option in cancer treatment", Clin Transl Oncol, 13, pp.363~367 (2011)
- Howlett HC, "Metformin in the management of type 2 diabetes", Diabet Med, 6, pp.179~180 (1989)
- Algire C, "Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth", Endocr Relat Cancer, 15, pp.833~839 (2008)
- Belfiore A, "Insulin receptor isoforms and insulin receptor", insulin-like growth factor receptor hybrids in physiology and disease, 2009, pp.30, 586~623
- Cao X, "The clinical effect of metformin on the survival of lung cancer patients with diabetes : a comprehensive systematic review and metaanalysis of retrospective studies", J Cancer, 8, pp.2532~2541 (2017)
- Dowling RJ, "Understanding the benefit of metformin use in cancer treatment", BMC Med, 9, pp.33~ (2011)
- Gotlieb WH, "In vitro metformin anti-neoplastic activity in epithelial ovarian cancer", Gynecol Oncol, 110, pp.246~250 (2008)
- Bowker SL, "Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin", Diabetes Care, 29, pp.254~258 (2006)
- Barker BE, "Human mammary slices in organ xulture. I. Method of culture and preliminary observations on the effect of insulin", Exp Cell Res, 35, pp.437~448 (1964)
- Rosenfeld RG, "Insulin-like growth factors and the basis of growth", N Engl J Med, 349, pp.2184~2186 (2003)
- Del Giudice ME, "Insulin and related factors in premenopausal breast cancer risk", Breast Cancer Res Treat, 47, pp.111~120 (1998)